BXP, Inc. earnings call
AI demand accelerating in San Francisco and New York
BXP reported a strong Q1 with FFO per share above expectations and raised its full-year guidance. The company highlighted robust leasing activity across all markets, driven significantly by AI companies, and expressed confidence in its occupancy growth targets. Management is progressing on its capital plan, including asset sales and de-risking its development pipeline. Q1 FFO of $1.59/share beat guidance by $0.02; FY26 guidance raised by $0.01 to $6.90-$7.04.
Buzzberg read AI demand accelerating in San Francisco and New York BXP reported a strong Q1 with FFO per share above expectations and raised its full-year guidance. The company highlighted robust leasing activity across all markets, driven significantly by AI companies, and expressed confidence in its occupancy growth targets. Management is progressing on its capital plan, including asset sales and de-risking its development pipeline. Q1 FFO of $1.59/share beat guidance by $0.02; FY26 guidance raised by $0.01 to $6.90-$7.04. Read full analysisCollapse analysis
BXP reported a strong Q1 with FFO per share above expectations and raised its full-year guidance. The company highlighted robust leasing activity across all markets, driven significantly by AI companies, and expressed confidence in its occupancy growth targets. Management is progressing on its capital plan, including asset sales and de-risking its development pipeline. Q1 FFO of $1.59/share beat guidance by $0.02; FY26 guidance raised by $0.01 to $6.90-$7.04.
- Leasing activity strong: 1.1M sq ft in Q1; pipeline of 1.7M sq ft under negotiation.
- Occupancy up to 87.4%, with 3.5% spread to leased; management confident of reaching 89% by year-end.
- AI companies (OpenAI, Anthropic, Databricks, etc.) are a major demand driver, particularly in San Francisco and New York.
What matters now
The highest-signal changes from the call.
Occupancy target of 89% by year-end 2026
343 Madison pre-leasing to reach 56% committed
Show 3 more callouts
Office transaction volume up 72% year-over-year
Raised $1.2 billion in net sale proceeds since investor conference
Raised 2026 FFO guidance by a penny at midpoint
Actuals
| Metric | Reported | Change |
|---|---|---|
| Revenue | $0.8721B | -1% QoQ |
| EPS | $0.64 | Reported |
| Gross margin | 59.07% | Reported |
| Operating margin | 26.12% | Reported |
| Free cash flow | $-0.1318B | Reported |
| Capex | $0.2883B | Reported |
Management read
Upbeat
Management expressed strong confidence in leasing momentum, occupancy gains, and progress on asset sales and developments, with multiple positive references to market strength and outperformance.
Management AI read
Management highlighted that AI is driving significant leasing demand, with direct benefits from AI companies in San Francisco, New York, and Seattle, and indirect benefits from companies serving the AI industry. They noted that AI demand is accelerating, with 80% of first-quarter leasing demand in San Francisco coming from AI companies, and that new AI tenants are expanding in their portfolio.
Investment and capacity
Leasing capital expenditure was higher in Q1 due to a significant amount of lease commencements, including early renewals, but management expects it to normalize while still exceeding previous levels for the year. They are also investing in development projects, notably 343 Madison Avenue, and expect to complete its recapitalization in 2026.
Companiesreturns since call
Customers
Databricks is one of many expanding AI firms that are leasing space from BXP, contributing to strong occupancy gains.
Evidence
“Databricks, Perplexity, Decagon, Harvey AI, Sierra AI, Snowflake, to name a few, with Decagon and Snowflake being new tenants in the BXP roster.”
BXP sold its stake in a building fully leased to Marriott, highlighting the strong value of such stabilized assets in the current market.
Evidence
“The 743,000 square foot building is fully leased to Marriott and sold for a gross price of $430 million or $589 a square foot and a 6.8% initial cap rate.”
AstraZeneca has started paying rent on BXP's development ahead of schedule, a positive sign for the delivery and cash flow of the project.
Evidence
“AstraZeneca already commenced cash rent payments as of April 1st, and we expect to deliver the project by June 1st at the latest.”
OpenAI and Anthropic are among the most significant drivers of new office demand in San Francisco and New York, contributing to BXP's leasing momentum.
Evidence
“Open AI and Anthropic are clearly the most recognizable expansions. but there are many meaningful space occupiers expanding across our markets.”
Supply-chain alpha · 4returns since call
BXP is taking back space from a defaulted tenant and expects to collect termination income covering nearly 12 months of potential downtime.
Evidence
“This quarter we received a termination payment totaling $6.25 million, which covers both the write-off from last quarter as well as nearly 12 months of potential downtime in rent.”
Strong leasing and occupancy gains in the first quarter are leading to a faster-than-expected pickup in occupied space, but this is also driving higher transaction costs (TIs) as new leases commence.
Evidence
“What drove the leasing cost this quarter was really a very significant amount of lease commencements, basically two times what we normally see.”
BXP expects to sign a Letter of Intent with a life science company for 49,000 square feet of office space, illustrating a shift from lab to office demand in the life science sector.
Evidence
“We signed the letter of intent last night for a 49,000 square foot life science company that's going to take 49,000 square feet of office space at one of our buildings.”
BXP is successfully monetizing land for residential development, leveraging a unique strategy to create value beyond traditional office use.
Methodology & coverage
Management-only analysis. All 7 validated company mentions are shown. Reported actuals and forward guidance are kept separate. Public evidence is limited to eight short attributed quotes. AI-generated analysis can be incomplete or wrong; verify important claims against the original source.